Know How Bexagliflozin Stacks Up to Other SGLT2 Inhibitors

New bexagliflozin (Brenzavvy) will try to shake up the SGLT2 inhibitor market.

That’s because bexagliflozin will cost about $50/month...versus about $600/month for other SGLT2 inhibitors (dapagliflozin, etc).

But bexagliflozin won’t be covered by most payers yet...and it will only be available through a single online pharmacy at first. Expect distribution to broaden over the next couple months.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote